Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple Sclerosis: An Ethnically Diverse Disease with Worldwide Equity Challenges Accessing Care.

Neurology international·2026
Same author

Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.

Clinical lung cancer·2025
Same author

Latin American RAND/UCLA modified Delphi consensus recommendations for management and treatment of adult MOGAD patients in clinical practice.

Multiple sclerosis and related disorders·2025
Same author

Advances in Multiple Sclerosis.

Biomedicines·2025
Same author

Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD.

Multiple sclerosis and related disorders·2025
Same author

Multiple sclerosis in Central America and Caribbean countries: frequency and clinical characterization of an emergent disease.

Frontiers in epidemiology·2024
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Tovaxin for multiple sclerosis.

Victor M Rivera1

  • 1Baylor College of Medicine, Houston, Texas 77030, USA. vrivera@bcm.edu

Expert Opinion on Biological Therapy
|May 14, 2011
PubMed
Summary
This summary is machine-generated.

Tovaxin, a T-cell immunotherapy for multiple sclerosis (MS), uses myelin-reactive lymphocytes. While complex, its efficacy in MS requires further clinical validation.

More Related Videos

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Related Experiment Videos

Last Updated: Jun 2, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
08:40

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis

Published on: February 28, 2021

Area of Science:

  • Immunology
  • Neuroscience
  • Cellular Therapy

Background:

  • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
  • Tovaxin is a personalized autologous T-cell immunotherapy investigated for MS treatment.

Purpose of the Study:

  • To review the production process of Tovaxin, a myelin-reactive T-cell immunotherapy.
  • To discuss historical aspects, T-cell acquisition, and attenuation techniques for Tovaxin.
  • To examine clinical trial results and limitations of Tovaxin in MS.

Main Methods:

  • Review of Tovaxin production: T-cell acquisition, myelin-reactive subset identification, ex vivo expansion, and irradiation for attenuation.
  • Reintroduction of attenuated T-cells into the donor to induce an immune response against autoreactive T-cells targeting myelin.
  • Analysis of historical data and clinical trial outcomes for Tovaxin.

Main Results:

  • The production of Tovaxin involves complex steps including T-cell manipulation and attenuation.
  • The process aims to generate an immune response against myelin-damaging T-cells in MS patients.
  • Clinical results from trials are discussed, highlighting the current understanding of Tovaxin's performance.

Conclusions:

  • T-cell vaccination with Tovaxin is a complex procedure with identified limitations.
  • Further scientific and clinical evidence is necessary to establish the efficacy of Tovaxin for multiple sclerosis.
  • The therapeutic potential of Tovaxin in MS necessitates continued research and validation.